Galena Biopharma (GALE) Misses Q3 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Galena Biopharma Reports Third Quarter 2015 Financial Results and Announces Exclusive Focus on Its Clinical Development Programs With Planned Divestiture of the Commercial Business
November 9, 2015 4:07 PM ESTClinical development immunotherapy programs make significant advances with new trials including a NeuVax Phase 2 clinical trial in DCIS and encouraging Phase 2a data for GALE-301 Commercial operations and products, Abstral® (fentanyl) Sublingual Tablets and Zuplenz® (ondansetron) Oral Soluble, to be divested Webcast and conference call scheduled for today at 2:00 p.m. P.T. / 5:00 p.m. E.T.
SAN RAMON, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that... More
Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting
November 9, 2015 7:05 AM ESTSAN RAMON, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's GALE-301 and GALE-302 clinical programs were presented at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland. The data presented was on the primary vaccine series (PVS) from a randomized Phase 1b trial with GALE-301 (E39) and GALE-302 (E39' variant of E39; previously named J65) that are folate... More
Galena Biopharma Presents GALE-302 Preliminary Immunologic Data Optimizing GALE-301 at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting
November 9, 2015 7:05 AM ESTSAN RAMON, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care, today announced that data from the Company's GALE-301 and GALE-302 clinical programs were presented at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, Maryland. The data presented was on the primary vaccine series (PVS) from a randomized Phase 1b trial with GALE-301 (E39) and GALE-302 (E39' variant of E39; previously named J65) that are folate... More
